NCT05021900
Breast Cancer Type: HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Serine-Threonine Kinase Inhibitor

Key Eligibility Criteria:

Gender: Female
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with HER2+ breast cancer; Patients with prior exposure to PI3K inhibitors (e.g. Piqray/alpelisib); Patients with symptomatic uncontrolled brain metastasis
https://ClinicalTrials.gov/show/NCT05021900